Compare CWBC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWBC | SLN |
|---|---|---|
| Founded | 1989 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 678.0M |
| IPO Year | 2000 | 2010 |
| Metric | CWBC | SLN |
|---|---|---|
| Price | $25.81 | $13.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $28.63 | ★ $42.60 |
| AVG Volume (30 Days) | 241.3K | ★ 1.6M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | ★ 344.44 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | N/A | ★ $559,000.00 |
| Revenue This Year | $39.58 | N/A |
| Revenue Next Year | $17.64 | N/A |
| P/E Ratio | $42.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.79 | $4.19 |
| 52 Week High | $28.17 | $17.58 |
| Indicator | CWBC | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 56.45 |
| Support Level | $24.75 | $5.24 |
| Resistance Level | $27.95 | $17.58 |
| Average True Range (ATR) | 0.50 | 1.00 |
| MACD | 0.08 | -0.09 |
| Stochastic Oscillator | 84.21 | 36.20 |
Community West Bancshares is a bank holding company whose principal business is to serve as the holding company for its wholly-owned subsidiary Community West Bank N.A. Through CWB, the company provides a variety of financial products and full-service Banking Centers within California's Greater Sacramento, San Joaquin Valley, and Central Coast regions, that provide Commercial Lending, Real Estate, Agribusiness, Private Banking, and Cash Management Departments. The company has one reportable segment: Banking operations. Loans and leases, investment securities, interest-bearing deposits and non-interest income provide the revenues of the banking operation.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.